Ken Griffin Kempharm, Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	N/A	113,500 Added 567.5%	133,500 $659,000
Q2 2024 Aug 14, 2024	SELL	N/A	-8,765 Reduced 30.47%	20,000 $98,000
Q1 2024 May 15, 2024	SELL	N/A	-56,400 Reduced 66.22%	28,765 $142,000
Q4 2023 Feb 14, 2024	BUY	N/A	18,865 Added 28.45%	85,165 $420,000
Q3 2023 Nov 14, 2023	SELL	N/A	-18,400 Reduced 21.72%	66,300 $327,000
Q2 2023 Aug 14, 2023	SELL	$4.94 - $6.29 $100,282 - $127,687	-20,300 Reduced 19.33%	84,700 $418,000
Q1 2023 May 15, 2023	SELL	$4.13 - $6.27 $571,179 - $867,140	-138,300 Reduced 56.84%	105,000 $577,000
Q4 2022 Feb 14, 2023	SELL	$4.12 - $5.62 $95,996 - $130,946	-23,300 Reduced 8.74%	243,300 $1.12 Million
Q3 2022 Nov 14, 2022	BUY	$4.5 - $6.85 $86,850 - $132,205	19,300 Added 7.8%	266,600 $1.66 Million

116

26.1M

591K

242K

Ticker KMPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,493,600
Market Cap $170M
Description
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds t...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.